2,483 results on '"Baccarani, M."'
Search Results
2. A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias
3. Differences among young adults, adults and elderly chronic myeloid leukemia patients
4. Treatment and outcome of 2904 CML patients from the EUTOS population-based registry
5. Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients
6. Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia
7. The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia
8. INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph1 acute lymphoblastic leukemia
9. Reply to Constance et al.
10. Long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib
11. Mutations and long-term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis
12. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries
13. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview
14. Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: Inclusion of quality of life and other patient-reported outcomes
15. Therapy of Adult Acute Lymphoblastic Leukemia. Preliminary Results of the GIMEMA ALL/0288 Study
16. Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study
17. The EUTOS prognostic score: review and validation in 1288 patients with CML treated frontline with imatinib
18. MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients
19. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
20. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome
21. Ruxolitinib- but not fedratinib-induced extreme thrombocytosis: the combination therapy with hydroxyurea and ruxolitinib is effective in reducing platelet count and splenomegaly/constitutional symptoms
22. Ponatinib in Refractory Ph-Positive Leukemias: A Phase 2 Trial
23. Treatment-free remission in chronic myeloid leukemia: floating between expectation and evidence
24. Differences among young adults, adults and elderly chronic myeloid leukemia patients
25. Chronic myelogenous leukemia: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
26. Leucemia mieloide cronica: valutazione dei costi e degli end-point clinici con il sistema LabNet
27. Profiling of drug-metabolizing enzymes/transporters in CD33+ acute myeloid leukemia patients treated with Gemtuzumab-Ozogamicin and Fludarabine, Cytarabine and Idarubicin
28. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib
29. Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance
30. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
31. Intensification of GVHD prophylaxis with low-dose ATG-F before allogeneic PBSC transplantation from HLA-identical siblings in adult patients with hematological malignancies: results from a retrospective analysis
32. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results
33. Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase
34. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF
35. IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis
36. A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients
37. Antiblastic chemotherapy for haematologic malignancies and second tumours
38. Different isoforms of the B-cell mutator activation-induced cytidine deaminase are aberrantly expressed in BCR–ABL1-positive acute lymphoblastic leukemia patients
39. Kinetics of Th1/Th2 cytokines and lymphocyte subsets to predict chronic GVHD after allo-SCT: results of a prospective study
40. Ascorbic acid inhibits antitumor activity of bortezomib in vivo
41. Molecular profile of CD34+ stem/progenitor cells according to JAK2V617F mutation status in essential thrombocythemia
42. The molecular anatomy of the FIP1L1-PDGFRA fusion gene
43. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib
44. WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia
45. Cryotherapy in the prevention of oral mucositis in patients receiving low-dose methotrexate following myeloablative allogeneic stem cell transplantation: a prospective randomized study of the Gruppo Italiano Trapianto di Midollo Osseo nurses group
46. Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients
47. Identification of a molecular signature predictive of sensitivity to differentiation induction in acute myeloid leukemia
48. The NF-κB pathway blockade by the IKK inhibitor PS1145 can overcome Imatinib resistance
49. Effects of granulocyte colony stimulating-factor in a rat model of acute liver injury
50. Dual tyrosine kinase inhibitors in chronic myeloid leukemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.